The living medicine inside us: in vitro therapeutic prospects of human gut bacteria
Gut microbial metabolism is intimately coupled to host health and disease. Recent knowledge on potential health benefits of gut microbiome lays the groundwork for development of novel therapeutic strategies. But how microbiota-derived metabolites impact on host-microbiome crosstalk remains untapped...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Gut Microbes Reports |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/29933935.2025.2480093 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849724883333808128 |
|---|---|
| author | K. M. Salim Andalib Fabliha Bashashat Rodosy Ahsan Habib |
| author_facet | K. M. Salim Andalib Fabliha Bashashat Rodosy Ahsan Habib |
| author_sort | K. M. Salim Andalib |
| collection | DOAJ |
| description | Gut microbial metabolism is intimately coupled to host health and disease. Recent knowledge on potential health benefits of gut microbiome lays the groundwork for development of novel therapeutic strategies. But how microbiota-derived metabolites impact on host-microbiome crosstalk remains untapped from therapeutic perspectives. In this study, six gut bacteria sourced from a fecal pool of forty healthy donors were cultured in three distinct growth media. Subsequently, the bacteria were identified through 16S rRNA gene sequencing and subjected to metabolite extraction to evaluate their anti-microbial, anti-oxidant and anti-thrombotic potential. Findings reveal strong anti-oxidant activities in the metabolic-extracts from all the isolates. Metabolites derived from Lactobacillus rhamnosus, Priestia flexa and Bacillus subtiilis inhibited the growth of clinically pathogenic strains Escherichia coli ATCC-8739, Salmonella typhi ATCC-1408 and Staphylococcus aureus ATCC-6538. Escherichia fergusonii originated metabolites demonstrated the highest efficacy in lysing blood clots compared to streptokinase. Additionally, extracts from all the isolates exhibited significant ability to delay coagulation time, competing with standard warfarin. Thus, the findings of our early-stage study provide novel insights into metabolomic functions of gut microbiota. This study underscores the significance of exploring these active metabolites for prospective therapeutic and clinical exploration at the intersection of drug discovery and live bio-therapeutics. |
| format | Article |
| id | doaj-art-020ea91274bf42cbbc4027d7e9f7b310 |
| institution | DOAJ |
| issn | 2993-3935 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Gut Microbes Reports |
| spelling | doaj-art-020ea91274bf42cbbc4027d7e9f7b3102025-08-20T03:10:37ZengTaylor & Francis GroupGut Microbes Reports2993-39352025-12-012110.1080/29933935.2025.2480093The living medicine inside us: in vitro therapeutic prospects of human gut bacteriaK. M. Salim Andalib0Fabliha Bashashat Rodosy1Ahsan Habib2Biotechnology and Genetic Engineering Discipline, Life Science School, Khulna University, Khulna, BangladeshDepartment of Microbiology, Bhashasoinik Gaziul Haque Institute of Bioscience, Bogura, BangladeshBiotechnology and Genetic Engineering Discipline, Life Science School, Khulna University, Khulna, BangladeshGut microbial metabolism is intimately coupled to host health and disease. Recent knowledge on potential health benefits of gut microbiome lays the groundwork for development of novel therapeutic strategies. But how microbiota-derived metabolites impact on host-microbiome crosstalk remains untapped from therapeutic perspectives. In this study, six gut bacteria sourced from a fecal pool of forty healthy donors were cultured in three distinct growth media. Subsequently, the bacteria were identified through 16S rRNA gene sequencing and subjected to metabolite extraction to evaluate their anti-microbial, anti-oxidant and anti-thrombotic potential. Findings reveal strong anti-oxidant activities in the metabolic-extracts from all the isolates. Metabolites derived from Lactobacillus rhamnosus, Priestia flexa and Bacillus subtiilis inhibited the growth of clinically pathogenic strains Escherichia coli ATCC-8739, Salmonella typhi ATCC-1408 and Staphylococcus aureus ATCC-6538. Escherichia fergusonii originated metabolites demonstrated the highest efficacy in lysing blood clots compared to streptokinase. Additionally, extracts from all the isolates exhibited significant ability to delay coagulation time, competing with standard warfarin. Thus, the findings of our early-stage study provide novel insights into metabolomic functions of gut microbiota. This study underscores the significance of exploring these active metabolites for prospective therapeutic and clinical exploration at the intersection of drug discovery and live bio-therapeutics.https://www.tandfonline.com/doi/10.1080/29933935.2025.2480093Gut bacteriabacteria-derived metabolitestherapeutic prospectsbiotherapeuticsgut healthprobiotics |
| spellingShingle | K. M. Salim Andalib Fabliha Bashashat Rodosy Ahsan Habib The living medicine inside us: in vitro therapeutic prospects of human gut bacteria Gut Microbes Reports Gut bacteria bacteria-derived metabolites therapeutic prospects biotherapeutics gut health probiotics |
| title | The living medicine inside us: in vitro therapeutic prospects of human gut bacteria |
| title_full | The living medicine inside us: in vitro therapeutic prospects of human gut bacteria |
| title_fullStr | The living medicine inside us: in vitro therapeutic prospects of human gut bacteria |
| title_full_unstemmed | The living medicine inside us: in vitro therapeutic prospects of human gut bacteria |
| title_short | The living medicine inside us: in vitro therapeutic prospects of human gut bacteria |
| title_sort | living medicine inside us in vitro therapeutic prospects of human gut bacteria |
| topic | Gut bacteria bacteria-derived metabolites therapeutic prospects biotherapeutics gut health probiotics |
| url | https://www.tandfonline.com/doi/10.1080/29933935.2025.2480093 |
| work_keys_str_mv | AT kmsalimandalib thelivingmedicineinsideusinvitrotherapeuticprospectsofhumangutbacteria AT fablihabashashatrodosy thelivingmedicineinsideusinvitrotherapeuticprospectsofhumangutbacteria AT ahsanhabib thelivingmedicineinsideusinvitrotherapeuticprospectsofhumangutbacteria AT kmsalimandalib livingmedicineinsideusinvitrotherapeuticprospectsofhumangutbacteria AT fablihabashashatrodosy livingmedicineinsideusinvitrotherapeuticprospectsofhumangutbacteria AT ahsanhabib livingmedicineinsideusinvitrotherapeuticprospectsofhumangutbacteria |